DK1020462T3 - Heterocykliske forbindelser og antitumormiddel indeholdende disse som aktiv ingrediens - Google Patents

Heterocykliske forbindelser og antitumormiddel indeholdende disse som aktiv ingrediens

Info

Publication number
DK1020462T3
DK1020462T3 DK98933922T DK98933922T DK1020462T3 DK 1020462 T3 DK1020462 T3 DK 1020462T3 DK 98933922 T DK98933922 T DK 98933922T DK 98933922 T DK98933922 T DK 98933922T DK 1020462 T3 DK1020462 T3 DK 1020462T3
Authority
DK
Denmark
Prior art keywords
active ingredient
heterocyclic compounds
agents containing
tumor agents
tumor
Prior art date
Application number
DK98933922T
Other languages
Danish (da)
English (en)
Inventor
Seiichiro Kawashima
Toshiyuki Matsuno
Shinichi Yaguchi
Tetsuo Watanabe
Masahiro Inaba
Original Assignee
Zenyaku Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zenyaku Kogyo Kk filed Critical Zenyaku Kogyo Kk
Application granted granted Critical
Publication of DK1020462T3 publication Critical patent/DK1020462T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK98933922T 1997-07-24 1998-07-24 Heterocykliske forbindelser og antitumormiddel indeholdende disse som aktiv ingrediens DK1020462T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP19880497 1997-07-24
PCT/JP1998/003308 WO1999005138A1 (fr) 1997-07-24 1998-07-24 Composes heterocycliques et agent antitumoral contenant lesdits composes utilises comme ingredients actifs

Publications (1)

Publication Number Publication Date
DK1020462T3 true DK1020462T3 (da) 2004-04-26

Family

ID=16397198

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98933922T DK1020462T3 (da) 1997-07-24 1998-07-24 Heterocykliske forbindelser og antitumormiddel indeholdende disse som aktiv ingrediens

Country Status (11)

Country Link
US (1) US6251900B1 (ko)
EP (1) EP1020462B1 (ko)
JP (1) JP4276376B2 (ko)
KR (1) KR100563514B1 (ko)
CN (1) CN1129597C (ko)
AU (1) AU727013B2 (ko)
CA (1) CA2297326C (ko)
DE (1) DE69821633T2 (ko)
DK (1) DK1020462T3 (ko)
ES (1) ES2213286T3 (ko)
WO (1) WO1999005138A1 (ko)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE305465T1 (de) 1998-11-17 2005-10-15 Kumiai Chemical Industry Co Pyrimidinylbenzimidazol- und triazinylbenzimidazol-derivate und agrikulte/hortikulte fungizide
JP4709388B2 (ja) * 1999-01-25 2011-06-22 全薬工業株式会社 複素環式化合物及びそれを有効成分とする抗腫瘍剤
US6218408B1 (en) 1999-06-30 2001-04-17 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
US6989379B1 (en) 1999-04-22 2006-01-24 H. Lundbick A/S Selective NPY (Y5) antagonists
US6340683B1 (en) * 1999-04-22 2002-01-22 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
PT1183245E (pt) * 1999-04-22 2007-07-12 Lundbeck & Co As H Antagonistas selectivos de npy (y5)
US7273880B2 (en) 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
US6225330B1 (en) 1999-06-30 2001-05-01 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (tricyclics)
US6222040B1 (en) 1999-06-30 2001-04-24 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (tricyclics)
US6214853B1 (en) 1999-06-30 2001-04-10 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
US6943161B2 (en) * 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
CN1310907C (zh) * 2001-04-27 2007-04-18 全药工业株式会社 杂环化合物和以其为有效成分的抗肿瘤药
ES2389253T3 (es) 2002-10-25 2012-10-24 Zenyaku Kogyo Kabushiki Kaisha Compuestos heterocíclicos y agentes antitumorales que comprenden los mismos como ingrediente activo
EP2316831B1 (en) * 2002-11-21 2013-03-06 Novartis AG 2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
US20050107374A1 (en) * 2003-10-21 2005-05-19 Amgen Inc. Substituted heterocyclic compounds and methods of use
CA2561406C (en) * 2004-03-31 2012-07-03 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and anti-malignant-tumor agent comprising the same as effective component
AU2005286592A1 (en) * 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
JP5089377B2 (ja) * 2005-03-11 2012-12-05 全薬工業株式会社 複素環式化合物を有効成分とする免疫抑制剤及び抗腫瘍剤
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US20070244110A1 (en) * 2006-04-14 2007-10-18 Zenyaku Kogyo Kabushiki Kaisha Treatment of prostate cancer, melanoma or hepatic cancer
WO2008032041A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives having inhibitory activity against pi3k enzymes
WO2008032091A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032036A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab 6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032089A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
US20090233926A1 (en) * 2006-09-14 2009-09-17 Astrazeneca 2-benzimidazolyl-6-morpholino-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032033A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
JP2010503649A (ja) * 2006-09-14 2010-02-04 アストラゼネカ アクチボラグ ピリミジン誘導体
AU2008213808B2 (en) * 2007-02-06 2011-11-10 Novartis Ag PI 3-kinase inhibitors and methods of their use
WO2008147540A1 (en) * 2007-05-23 2008-12-04 New York University School Of Medicine S-triazine compounds, pharmaceutical compositions and methods of using the same
DK2409975T3 (en) 2007-11-22 2015-08-03 Zenyaku Kogyo Kk Solid dispersions comprising an amorphous body composed of a heterocyclic anti-tumor compound
WO2009120094A2 (en) * 2008-03-27 2009-10-01 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
US10022381B2 (en) 2008-05-23 2018-07-17 Pfizer Inc. Triazine compounds as PI3 kinase and mTOR inhibitors
PT2294072T (pt) * 2008-05-23 2017-05-29 Wyeth Llc Compostos de triazina como inibidores de p13 quinase e mtor
WO2010012745A2 (en) * 2008-07-29 2010-02-04 Boehringer Ingelheim International Gmbh Benzimidazoles
EP2397479A4 (en) 2009-02-12 2012-08-01 Astellas Pharma Inc HETERO RING DERIVATIVE
WO2010096619A1 (en) * 2009-02-23 2010-08-26 Wyeth Llc Process, purification and crystallization of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
TW201038567A (en) 2009-03-27 2010-11-01 Pathway Therapeutics Ltd Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2011005119A1 (en) * 2009-07-07 2011-01-13 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
GB201007227D0 (en) 2010-04-30 2010-06-16 Univ Basel Piperazinotriazines
AU2011290189B8 (en) 2010-08-10 2015-02-19 Astellas Pharma Inc. Heterocyclic compound
DK2691384T3 (en) 2011-03-28 2017-01-16 Mei Pharma Inc (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND THEIR SUBSTANCES CONCERNING THE USE OF THE USE
WO2013046136A1 (en) 2011-09-27 2013-04-04 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
WO2014055647A1 (en) * 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
WO2014090147A1 (zh) * 2012-12-14 2014-06-19 上海恒瑞医药有限公司 嘧啶类衍生物及其可药用盐、其制备方法及其在医药上的应用
MX355945B (es) 2013-03-14 2018-05-07 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
CN105175410B (zh) * 2015-10-14 2018-01-05 湖南华腾制药有限公司 三嗪类化合物及其制备方法和抗肿瘤应用
CA3063976A1 (en) 2017-05-23 2018-11-29 Mei Pharma, Inc. Combination therapy
MA49921A (fr) 2017-08-14 2021-05-12 Mei Pharma Inc Polythérapie
US20220378799A1 (en) * 2019-06-06 2022-12-01 Beijing Tide Pharmaceutical Co., Ltd. 2, 4, 6-tri-substituted pyrimidine compound as atr kinase inhibitor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0948776A (ja) * 1994-09-26 1997-02-18 Dai Ichi Seiyaku Co Ltd ピリミジニルピラゾール誘導体

Also Published As

Publication number Publication date
CA2297326A1 (en) 1999-02-04
CN1271355A (zh) 2000-10-25
CN1129597C (zh) 2003-12-03
EP1020462B1 (en) 2004-02-11
AU8357598A (en) 1999-02-16
AU727013B2 (en) 2000-11-30
CA2297326C (en) 2007-03-20
JP4276376B2 (ja) 2009-06-10
DE69821633T2 (de) 2004-12-16
KR20010021860A (ko) 2001-03-15
ES2213286T3 (es) 2004-08-16
WO1999005138A1 (fr) 1999-02-04
KR100563514B1 (ko) 2006-03-27
DE69821633D1 (de) 2004-03-18
EP1020462A4 (en) 2003-01-08
US6251900B1 (en) 2001-06-26
EP1020462A1 (en) 2000-07-19

Similar Documents

Publication Publication Date Title
DK1020462T3 (da) Heterocykliske forbindelser og antitumormiddel indeholdende disse som aktiv ingrediens
NO993868D0 (no) 3-piperidyl-4-oksokinazolin-derivater og medisinske preparater som inneholder slike
IS5058A (is) Samverkandi súlfónýlþvagefnis-glitasónsblöndur við sykursýki
NO20001631L (no) 2-metyl-tieno-benzodiazepin formulering
DK1028961T5 (da) Pleuromutilinderivater som antimikrobielle midler
ID22878A (id) Komposisi aktif secara terapi
DK1015434T3 (da) Ny pyrimidin-4-on og pyrimidin-4-thion som fungicid
NO20000048L (no) Triazolforbindelser og deres anvendelse som dopamin-D3- ligander
ATE242249T1 (de) Herbizid aktive 3-hydroxy-4-aryl-5- oxopyrazolinderivate
NO20021401D0 (no) Konazolinforbindelser og farmasöytiske preparater inneholdende slike forbindelser
NO980546D0 (no) Farmasöytiske midler
NO982296L (no) Triaromatiske forbindelser, preparater inneholdende disse og deres anvendelse
NO984106D0 (no) Azolobenzazepin-derivater som neurologisk aktive midler
NO996578D0 (no) Urokinase-inhibitorer
NO308294B1 (no) Dimetyl-3(aryl-but-3-enyl)-aminforbindelse som farmasøytiske forbindelser og anvendelse av disse
NO996584D0 (no) brukshjelp for absorberende gjenstand til engangsbruk
DE69805807D1 (de) Mikrobiozide n-sulfonylglycin-alkynyloxyphenethylamid-derivate
NO981121L (no) Substituerte aminoforbindelser og deres anvendelse som analgetisk virksomme stoffer
NO20006646D0 (no) Aminosyrederivater og legemidler inneholdende de samme som aktiv bestanddel
NO20000366D0 (no) O-substituerte hydroksycoumaranon-derivater som anti-tumor- og antimetastase-midler
NO973471D0 (no) Transdermal formulering
NO20013318L (no) Substituerte 2-aryliminoheterocykliske forbindelser og preparater inneholdende disse for anvendelse
DK0868911T3 (da) Rapamycinpræparater til oral indgivelse
FI973362A (fi) Transdermaalinen formula
ID18793A (id) Bahan penahan untuk pestisida